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Mafosfamide cyclohexylamine salt (D-17272), 4-hydro-peroxy-cyclophosphamide
(D-18864), and $-D-glucose-isophosphoramide mustard (D-19575, glufosfamide) are three
new generation oxazaphosphorine agents. The aim of the present study was to compare the
cell response to the action of these three oxazaphosphorines. The experiments were
performed in vitro on human acute myeloblastic leukemia ML-1 cells. After exposure of
ML-1 cells to the oxazaphosphorines, the size, viability and count of these cells were
determined. The research was conducted using the spectrophotometric MTT assay and the
electronic Beckman Coulter method. The temporary changes in the ML-1 cell size, viability
and count, were dependent on the oxazaphosphorine agent tested, its dose, and the time
intervals after its application. Among the three oxazaphosphorine agents, D-18864 proved to
be the most cytotoxic, and D-19575 was characterized by the lowest cytotoxicity. The results
suggest the possibility of using the electronic sizing and counting method and the MTT assay
as a rapid in vitro test for assessing leukemic cell sensitivity to the action of new potential
chemotherapeutic agents.
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Oxazaphosphorines are a class of alkylating agents,
widely used in chemotherapy. However, to improve
the therapeutic index of this class of chemothera-
peutic agents, new generation oxazaphosphorines
have been developed. Mafosfamide cyclohexylamine
salt (D-17272), 4-hydro-peroxy-cyclophosphamide
(D-18864), and$-D-glucose-isophosphoramide mus-
tard (D-19575, glufosfamide) are new oxazaphos-
phorine derivatives. The cell response to the action
of these alkylating compounds is still under ex-
perimental and clinical investigation (BODY and
YULE 2000; ENGEL et al. 2000; SEKER et al. 2000;
BLANEY et al. 2005; ZHANG et al. 2005a, 2005b;
LIANG et al. 2007; GIRAUD et al. 2010; MAZUR et al.
2011).
The influence of the new generation oxazaphos-
phorines on pathological hematopoietic cells is not
completely known yet. Available information on
the cytotoxic activity of D-17272, D-18864, and
D-19575 in human leukemic cells is still scarce
(STYCZYÑSKI et al. 2000a, 2000b; GOLDSTEIN et al.
2008; MAZUR et al. 2009, 2010; OPYDO-CHANEK
et al. 2010a, 2010b).
Therefore, the objective of the present study was
to evaluate in vitro cytotoxicity of three new
oxazaphosphorine agents on human acute myelo-
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blastic leukemia ML-1 cells. Temporary changes
in the size, viability and count of ML-1 cells sub-
jected to the exposure of D-17272, D-18864, and
D-19575, were analyzed using the electronic
Beckman Coulter method and the MTT assay.
Material and Methods
Cells
Human acute myeloblastic leukemia ML-1 cells
(European Collection of Cell Culture, ECACC,
Sigma Aldrich, Catalogue No. 88113007) were
maintained in RPMI 1640 (Gibco BRL Life Tech-
nologies) supplemented with 10% fetal calf serum
(GIBCO BRL Life Technologies), 2 mM L-glutamine
(Sigma Aldrich), and antibiotic antimycotic solu-
tion (AAS, Sigma Aldrich). AAS contained 20 units
of penicillin, 20 Fg streptomycin and 0.05 Fg am-
photericin B. Leukemic ML-1 cells were passaged
every third day. The cells grew expotentially at 37oC
in an atmosphere of 5% CO2 in air (HERAcell in-
cubator, KendroLab). The cultures were periodi-
cally tested for Mycoplasma infection.
Chemicals
Mafosfamide cyclohexylamine salt (D-17272,
CAS No. 84210-80-0), 4-hydro-peroxy-cyclophosphamide
(D-18864, CAS No. 39800-16-3) and glufosfa-
mide (D-19575, $-D-glucose-isophosphoramide
mustard, CAS No. 132682-98-5) were obtained
from NIOMECH (Bielefeld, Germany). D-17272,
D-18864 and D-19575 were dissolved in aqua pro
injectione (Polpharma). All solutions were freshly
prepared directly before treatment of ML-1 cells.
Agent doses and cell treatment
After a dilution of the cell suspension to a den-
sity of 15x104 cells/ml medium, ML-1 cells were
exposed for 30 min to the oxazaphosphorine agent.
D-18864 was applied at a dose of 10 Fg/ml me-
dium, D-19575 at a dose of 100 Fg/ml medium,
and D-17272 was given at doses of 10 Fg/ml and
100Fg/ml medium. The control material consisted
of untreated ML-1 cells. After 30 min treatment
with the oxazaphosphorine agent, leukemic ML-1
cells were centrifuged for 10 min at 1000 rpm and
the supernatant was discarded. Then the cells were
washed in 2 ml of PBS (BioMed) and pelletted by
centrifugation for 7 min. The wash and centrifuga-
tion were repeated once more and the cells resus-
pended in the complete RPMI 1640 medium.
ML-1 cell analysis
Temporary alterations occurring in human leu-
kemic ML-1 cells were assessed at 24h, 48h, and
72h after the cell exposure to the oxazaphosphorine
agent. At these three time intervals, the size, vi-
ability and count of ML-1 cells, were determined.
Beckman Coulter method of cell sizing and
counting
The electronic Beckman Coulter method was ap-
plied to determine ML-1 cell size and count. The
Beckman Coulter method of cell sizing and count-
ing is based on the detection and measurement of
changes in electrical resistance produced by a cell
suspended in a conductive liquid traversing through
a small aperture. The passage of each individual
cell momentarily modulates the impedance of the
electrical path between two electrodes located on
each side of the aperture. An electrical pulse, suit-
able for sizing and counting, results from the pas-
sage of each cell through the aperture. While the
amplitude of the produced electrical pulse depends
on the cell volume, the number of pulses indicates
the cell count.
Samples of ML-1 cell suspension were taken
from flasks and immediately diluted in ISOTON II
(Beckman Coulter filtered electrolyte solution based
on 0.9 % saline). 500 Fl of the cell suspension was
added to 4.5 ml of ISOTON II. After the dilution of
ML-1 cell suspension, individual leukemic cells were
measured using the Z2 Coulter counter (Beckman
Coulter, USA). The count and volume distributions
of ML-1 cells were obtained using the counter
equipped with a 100Fm diameter orifice. The flow
rate was 500Fl / 12.5 sec. The range for cell measu-
rement was determined as 162-10 370 fL. The cell
volume and count was analyzed at 851-10 370 fL.
The instrument was calibrated using 10Fm diame-
ter latex beads (Beckman Coulter CC size stan-
dard). The mean cell volume, modal peak and the
cell count, were determined using Z2 AccuComp
software (Beckman Coulter, USA).
MTT viability assay
The in vitro MTT test was designed for spectro-
photometrically determining the viability of cell
populations. MTT (3-[4,5-dimethylthiazol-2-yl]
-2,5-diphenyl tetrazolium bromide) is the key
component used in the MTT assay. In viable, me-
tabolically active cells, the tetrazolium ring is
cleaved, yielding formazan crystals. Changes in
the metabolic activity of cell populations result in a
concomitant change in the amount of formazan
formed.
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MTT (Sigma-Aldrich) was dissolved in RPMI
1640 medium, at a concentration of 5 mg/ml, and
filtered through a 0.2 Fm filter. 100 Fl of the yel-
low MTT solution was added to each well of a 24-
well plate containing 1 ml of the cell suspension.
The cells were then incubated at 37°C with 5%
CO2. A blank solution was prepared according to
the above procedure using complete medium with-
out cells. After the three-hour incubation period,
the resulting formazan crystals were dissolved
with 1 ml of acidified isopropanol (0.05 N HCl in
absolute isopropanol), and absorbance of the ob-
tained solution was measured at a wavelength of
570 nm using a Pharmacia Ultrospec III spectro-
photometer (Pharmacia). The extent of MTT con-
version in cells was also expressed as a percentage
value of the control.
Statistical evaluation
Statistical significance of differences in the
mean cell volume and the mean amount of for-
mazan formed as well as in the mean cell count,
were evaluated by an analysis of variance and the
Duncan’s new multiple range test.
Results
Effects of oxazaphosphorines on ML-1 cells
The influence of three new generation
oxazaphosphorines on human acute myeloblastic
leukemia ML-1 cells, was determined. The effects
of D-18864, D-17272, and D-19575, on the leuke-
mic cell size (Table 1 and Table 2, Fig. 1), and their
viability (Table 3, Fig. 2) and count (Table 4), ob-
served at 24h, 48h, and 72h after the oxazaphos-
phorine agent application, were compared.
Mean volume of ML-1 cells (Table 1, Fig. 1)
In comparison with the controls, the mean vo-
lume of ML-1 cells was increased in all the experi-
mental groups and at all three time intervals 24h,
48h, and 72h after the leukemic cell exposure to
the action of the oxazaphosphorine agents. Among
ML-1 cells treated with the oxazaphosphorine
agents, the greatest mean volume was obtained
when D-17272 was given at a higher dose of 100
Fg/ml medium, and the smallest mean volume of
the leukemic cells was observed after D-19575 ap-
plication, at the same dose. The increased mean
volume of ML-1 cells exposed to D-17272 at two
doses, 10 Fg/ml and 100 Fg/ml medium, appeared
to be dose-dependent. The mean volume was
found to be smaller in ML-1 cells treated with
D-17272, at a dose of 10 Fg/ml medium, than in
those exposed to D-18864 at the same dose.
Modal peak of the volume distribution curve
(Table 2, Fig. 1)
In relation to the controls, greater values in the
modal peaks of the volume distribution curves
were found in ML-1 cells exposed to the action of
the oxazaphosphorines, except for the value obtained
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Table 1
The mean volume of ML-1 cells after their exposure to the oxazaphosphorine agents
Group characteristic
Mean cell volume (fL)
24h 48h 72h
No. agent  given agent dose mean ± SD mean ± SD mean ± SD

































The data are presented as mean values ± standard deviation.
Statistically significant differences at P<0.05
Differences between groups:  different from Group I – 1, Group II – 2, Group III – 3, Group IV – 4, Group V – 5.
Differences within each group: different from 24h – 24h, 48h – 48h, 72h – 72h.
at 72h after D-17272 application at a higher dose
of 100 Fg/ml medium. The patterns of temporary
changes in the modal peak of the volume distribu-
tion curve are correlated with those of the mean
volume of ML-1 cells.
ML-1 cell viability (Table 3, Fig. 2)
The cell viability is correlated with the optical
density of formazan solution. Compared with the
controls, the optical density of formazan solution
decreased 24h, 48h, and 72h after the treatment of
ML-1 cells with D-18864, D-17272, and at 24h
and 72h after their exposure to the action of
D-19575. Among ML-1 cells treated with the
oxazaphosphorine agents, the values of the optical
density of formazan solution were found to be
greater following D-19575 application at a dose of
100 Fg/ml, and when D-17272 was given at a dose
of 10 Fg/ml medium, and smaller values were ob-
tained when D-18864 was applied at a dose of 10
Fg/ml and D-17272 at a dose of 100 g/ml medium.
The viability rate indicating the extent of MTT
conversion to formazan, and expressed as the per-
centage values of the controls, appeared to be dis-
tinctly reduced in ML-1 cells exposed to D-18864
at a dose of 10 Fg/ml and especially in those treated
with D-17272 at a dose of 100 Fg/ml medium.
ML-1 cell count (Table 4)
In comparison with the controls, the cell count of
ML-1 cells decreased in all experimental groups
and in all three time intervals at 24h, 48h, and 72h
after the leukemic cell exposure to the action of the
oxazaphosphorine agents. Among ML-1 cells treated
with the oxazaphosphorine agents, the smallest cell
number was found when D-17272 was given at a
higher dose of 100Fg/ml medium, and the greatest
number of the leukemic cells was encountered after
D-19575 application, at the same dose. A reduced
Fig. 1. The volume of ML-1 cells exposed to the oxazaphosphorines.
The volume distribution curves of ML-1 cells analyzed
with the Beckman Coulter counter. The peaks on the left
represent cellular debris, presumably apoptotic bodies and
necrotic cell fragments, which were excluded from the
analysis of the ML-1 cell volume.
Table 2
The modal peaks of the volume distribution curves of ML-1 cells exposed to the action
of D-17272, D-18864, and D-19575
Group characteristic Modal peak (fL)
No. agent given agent dose 24h 48h 72h
I D-18864 10 Fg/ml 3181 3628 3222
II D-17272 10 Fg/ml 2735 2290 1925
III D-17272 100 Fg/ml 3506 7437 871
IV D-19575 100 Fg/ml 1965 2168 1804
V control 1682 1804 1601
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count of ML-1 cells exposed to D-17272 at two
doses, 10 Fg/ml and 100 Fg/ml medium, appeared
to be dose-dependent. The cell number was ob-
served to be greater in ML-1 cells treated with
D-17272, at a dose of 10 Fg/ml medium, than in
those exposed to D-18864 at the same dose.
Discussion
The results of the present study have shown the
human acute myeloblastic leukemia ML-1 cell re-
sponse to the action of three new generation
oxazaphosphorines D-17272, D-18864, and D-19575.
Temporary alterations in the size, viability and
count of ML-1 cells, observed 24h, 48h and 72h
Fig. 2. Effects of the oxazaphosphorines on the viability rate
of ML-1 cells. The extent of MTT conversion to formazan
in ML-1 cells expressed as a percentage value of the
control. D-18864/10 - D-18864 applied at a dose of 10
Fg/ml medium; D-17272/10 - D-17272 applied at a dose of
10 Fg/ml medium; D-17272/100 - D-17272 applied at a
dose of 100 Fg/ml medium; D-19575/100 - D-19575
applied at a dose of 100 Fg/ml medium.
Table 3
The optical density of formazan solution determined after ML-1 cell exposure to the
oxazaphosphorine agents
Group characteristic Optical density of formazan solution (x10
-1)
24h 48h 72h
No. agent given agent dose mean ± SD mean ± SD mean ± SD

































For explanation of signs, see Table 1.
Table 4
The count of ML-1 cells after their exposure to the oxazaphosphorine agents
Group characteristic Cell count (x 10
3)
24h 48h 72h
No. agent given agent dose mean ± SD mean ± SD mean ± SD

































For explanation of signs, see Table 1.
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after their exposure to the oxazaphosphorines
agents, were dependent on the agent tested, its
dose, and the time intervals after its application.
Among the oxazaphosphorine agents, D-18864
appeared to be the most cytotoxic, and D-19575
was characterized by the lowest cytotoxicity. The
variable leukemic cell responses to the action of
the oxazaphosphorines, were found.
The cytotoxic effects of the oxazaphosphorines,
D-17272, D-18864, and D-19575, surely resulted
from their various action on human leukemic
ML-1 cells. However, the precise mechanisms re-
sponsible for cytotoxicity of these three
oxazaphosphorine agents on pathological hemato-
poietic cells have not yet been completely eluci-
dated. It is accepted that phosphoramide mustard
and acrolein are the major reactive alkylating
agents of D-17272 and D-18864. D-19575 con-
tains the direct alkylating moiety, isophosphora-
mide mustard. The reactive alkylating compounds
are involved in the toxicologic reactions because
they can bind to a variety of cellular molecules dis-
turbing the normal processes occurring in the cell.
Moreover, the cytotoxicity of these oxazaphos-
phorines is dependent on their pharmacokinetic
and pharmacodynamic properties (BODY and YULE
2000; ZHANG et al., 2005a, 2005b; LIANG et al.
2007; GIRAUD et al. 2010; MAZUR et al. 2011).
The changes in the metabolic activity and cell vi-
ability, the volume and count of leukemic ML-1
cells following D-17272, D-18864, and D-19575
application can result from various alterations oc-
curring in these cells at the molecular, biochemical
and morphological levels. In the previous publica-
tion it has been shown that damage caused by the
oxazaphosphorine agents in the hematopoietic
cells was manifested as DNA breakage, cell cycle
disruption, cell proliferation inhibition, mitotic ca-
tastrophe and programmed cell death – induction
(MAZUR 2002; MAZUR et al. 2009, 2010; OPYDO-
-CHANEK et al. 2010a, 2010b).
To summarize, the results of the present investi-
gations indicated that three analyzed parameters,
cell volume, viability, and cell count are important
in determining and comparing cytotoxic effects
observed in human leukemic cells after their expo-
sure to the new generation oxazaphosphorines. In
conclusion, the electronic sizing and counting
method and MTT assay can be used to study the
anticancer activity of newly synthesized and
tested, potential chemotherapeutic agents.
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